A Randomized, Double Masked, Active Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients with Neovascular Age-Related Macular Degeneration

Administered By

Awarded By

Contributors

Start/End

  • February 1, 2016 - June 29, 2018